KYC is one time exercise with a SEBI registered intermediary while dealing in securities markets (Broker/ DP/ Mutual Fund etc.). | No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.   |   Prevent unauthorized transactions in your account – Update your mobile numbers / email ids with your stock brokers. Receive information of your transactions directly from exchange on your mobile / email at the EOD | Filing Complaint on SCORES - QUICK & EASY a) Register on SCORES b) Mandatory details for filing complaints on SCORE - Name, PAN, Email, Address and Mob. no. c) Benefits - speedy redressal & Effective communication   |   BSE Prices delayed by 5 minutes... << Prices as on Dec 20, 2024 >>  ABB India 6923.8  [ -5.79% ]  ACC 2064.45  [ -2.43% ]  Ambuja Cements 548.85  [ -2.53% ]  Asian Paints Ltd. 2283.05  [ -0.43% ]  Axis Bank Ltd. 1072.1  [ -3.28% ]  Bajaj Auto 8786.65  [ -2.09% ]  Bank of Baroda 240.3  [ -3.20% ]  Bharti Airtel 1578.25  [ -1.34% ]  Bharat Heavy Ele 235.25  [ -2.89% ]  Bharat Petroleum 288.95  [ -1.92% ]  Britannia Ind. 4700.9  [ -1.70% ]  Cipla 1472.45  [ -2.22% ]  Coal India 382.75  [ -2.43% ]  Colgate Palm. 2750.95  [ -1.06% ]  Dabur India 501.9  [ -0.42% ]  DLF Ltd. 830.75  [ -3.86% ]  Dr. Reddy's Labs 1342.45  [ 1.24% ]  GAIL (India) 192.45  [ -0.59% ]  Grasim Inds. 2493.85  [ -1.72% ]  HCL Technologies 1911.2  [ -1.15% ]  HDFC 2729.95  [ -0.62% ]  HDFC Bank 1772.05  [ -1.19% ]  Hero MotoCorp 4339.85  [ -1.53% ]  Hindustan Unilever L 2334.95  [ -1.06% ]  Hindalco Indus. 623.75  [ -0.91% ]  ICICI Bank 1285.7  [ -0.12% ]  IDFC L 108  [ -1.77% ]  Indian Hotels Co 854  [ -3.03% ]  IndusInd Bank 930  [ -3.53% ]  Infosys L 1922.05  [ -1.34% ]  ITC Ltd. 464.6  [ -0.38% ]  Jindal St & Pwr 908.1  [ -1.51% ]  Kotak Mahindra Bank 1743.55  [ -1.04% ]  L&T 3630.6  [ -2.22% ]  Lupin Ltd. 2147.55  [ -0.68% ]  Mahi. & Mahi 2906.4  [ -3.60% ]  Maruti Suzuki India 10904.75  [ -0.46% ]  MTNL 52.47  [ -3.49% ]  Nestle India 2163.85  [ 0.12% ]  NIIT Ltd. 186.15  [ -5.41% ]  NMDC Ltd. 213.35  [ -0.35% ]  NTPC 333.3  [ -1.29% ]  ONGC 237.3  [ -1.92% ]  Punj. NationlBak 100.7  [ -2.71% ]  Power Grid Corpo 315.75  [ -1.90% ]  Reliance Inds. 1206  [ -2.00% ]  SBI 812.5  [ -2.44% ]  Vedanta 477.5  [ -2.99% ]  Shipping Corpn. 211.75  [ -3.77% ]  Sun Pharma. 1808.5  [ -0.81% ]  Tata Chemicals 1028.25  [ -2.94% ]  Tata Consumer Produc 889.75  [ -1.86% ]  Tata Motors 724  [ -2.73% ]  Tata Steel 140.85  [ -1.71% ]  Tata Power Co. 401.25  [ -2.75% ]  Tata Consultancy 4168.05  [ -2.42% ]  Tech Mahindra 1685.2  [ -3.97% ]  UltraTech Cement 11424.7  [ -2.14% ]  United Spirits 1545.75  [ -1.58% ]  Wipro 305.15  [ -2.41% ]  Zee Entertainment En 125.05  [ -4.14% ]  

Company Information

Indian Indices

  • Loading....

Global Indices

  • Loading....

Forex

  • Loading....

NEULAND LABORATORIES LTD.

20 December 2024 | 12:00

Industry >> Pharmaceuticals

Select Another Company

ISIN No INE794A01010 BSE Code / NSE Code 524558 / NEULANDLAB Book Value (Rs.) 999.07 Face Value 10.00
Bookclosure 15/07/2024 52Week High 18100 EPS 233.89 P/E 59.39
Market Cap. 17822.19 Cr. 52Week Low 4926 P/BV / Div Yield (%) 13.90 / 0.10 Market Lot 1.00
Security Type Other

NOTES TO ACCOUNTS

You can view the entire text of Notes to accounts of the company for the latest year
Year End :2024-03 

ii. Rights, preferences and restrictions attached to equity shares

The Company has only one class of equity shares having a par value of H10 per share. Each holder of equity shares is entitled to one vote per share.

The Company declares and pays dividends in Indian rupees. The dividend proposed by the Board of Directors is subject to approval of shareholders in the ensuing Annual General Meeting, except in case of interim dividend.

In the event of liquidation of the Company, the holders of equity shares will be entitled to receive the remaining assets of the Company, after distribution of all preferential amounts in proportion of their shareholding.

During the five years period ended March 31, 2024, no shares have been bought back/ issued for consideration other than Cash and no bonus shares have been issued.

Nature and purpose of reserves Capital reserve

Capital reserve was created on account of merger of Neuland Drugs & Pharmaceuticals Private Limited with the Company. The capital reserve can be utilised in accordance with the provisions of the Act.

Securities premium

The amount received in excess of face value of the equity shares is recognised in securities premium. In case of equity-settled share based payment transactions, the difference between fair value on grant date and face value of share is accounted as securities premium. This reserve is utilised in accordance with the provisions of the Act.

General reserve

General reserve is used from time to time to transfer profits from retained earnings for appropriation purposes.

Revaluation reserve

Revaluation reserve was created on account of revaluation of certain property, plant and equipment during the earlier years. Retained earnings

Retained earnings represent the Company's undistributed earnings after taxes.

FVTOCI equity instruments

The Company has elected to recognise the change in fair value of certain investments in other comprehensive income. These changes are accumulated within the FVTOCI equity instruments reserve within equity. The Company transfers amounts from this reserve to retained earnings when the relevant equity instruments are derecognised.

Remeasurement of defined benefit plan

The reserve represents the remeasurement gains/(losses) arising from the actuarial valuation of the defined benefit plan of the Company. The remeasurement gains/(losses) are recognized in other comprehensive income and accumulated under this reserve within equity. The amounts recognized under this reserve are not reclassified to statement of profit and loss.

(b) The above loans are secured by pari-passu first charge on property, plant and equipment (both present and future) and second charge (hypothecation) on the current assets of the Company. The term loans of 1 & 3 from banks are also secured by way of personal guarantees extended by Dr. Davuluri Rama Mohan Rao and Davuluri Sucheth Rao which was released w.e.f October 10, 2023.

(c) Vehicles loans outstanding to the tune of H1,059.97 (March 31, 2023: H459.57) are secured by hypothecation of specific vehicles against which the loan was availed. These vehicle loans are repayable in instalments ranging from 35 to 59 months from the date of the loan.

(d) All the above loans carry interest in the range of 1.8% to 8.6% per annum as at March 31, 2024 (March 31, 2023: 1.8% to 9.6% per annum).

(e) Refer Note 32 for the Maturity profile of borrowings including current maturities.

(i) Loans outstanding represent packing credit and working capital demand facility availed with various banks and carry interest linked to the respective bank's prime / base lending rate, and interest range @ Nil (March 31, 2023: 0.70% to 8.9% per annum).

(ii) The above loans with all working capital lenders are secured by way of pari-passu first charge on all the current assets of the Company and pari-passu second charge on Company's property, plant and equipment.

(iii) The quarterly returns submitted with banks are in agreement of the books of accounts

Gratuity

The Company has a defined benefit funded gratuity plan. Every employee who has completed five years or more of service gets a gratuity on departure at 15 days salary (last drawn salary) for each completed year of service. The Company has subscribed to a group gratuity scheme of Life Insurance Corporation of India (LIC), Kotak Gratuity Group Plan and SBI Life. Under the said policy, the eligible employees are entitled for gratuity upon their resignation or in the event of death in lumpsum after deduction of necessary taxes up to a maximum limit of H20.

The following table set out the status of the gratuity plan and the reconciliation of opening and closing balances of the present value and defined benefit obligation.

The sensitivity analysis presented above may not be representative of the actual change in the defined benefit obligation as it is unlikely that the change in assumptions would occur in isolation of one another as some of the assumptions may be correlated.

Furthermore, in presenting the above sensitivity analysis, the present value of the defined benefit obligation has been calculated using the projected unit credit method at the end of the reporting period, which is the same as that applied in calculating the defined benefit obligation liability recognised in the balance sheet.

There was no change in the methods and assumptions used in preparing the sensitivity analysis from prior years. There has been no change in the process used by the Company to manage its risks from prior periods.

Performance Obligation:

Sale of products: Performance obligation in respect of sale of goods is satisfied when control of the goods is transferred to the customer, generally on delivery of the goods and payment is generally due as per the terms of contract with customers

Sale of services: The performance obligation in respect of maintenance services is satisfied over a period of time and acceptance of the customer. In respect of these services, payment is generally due upon completion of maintenance period based on time elapsed and acceptance of the customer. In certain non-standard contracts, where the Company provides warranties in service of consumer durable goods, the same is accounted for as a separate performance obligation and a portion of the transaction price is allocated based on its relative standalone prices. The performance obligation for the warranty service is satisfied over a period of time based on time elapsed.

Remaining performance obligations

The aggregate value of transaction price allocated to unsatisfied (or partially satisfied) performance obligations in case of contracts for which revenues are recorded over a period of time is H1,151.93 (March 31, 2023: H1,475.36), which is expected to be fully recognised as revenue in the next year. No consideration from contracts with customers is excluded from the amount mentioned above and contract asset relating to partially satisfied performance obligations aggregates to H302.04 as at March 31, 2024 (March 31, 2023: H693.86)

(i) Details of CSR expenditure :

As per Section 135 of the Companies Act, 2013, a Company, meeting the applicability threshold, needs to spend at least 2% of its average net profit for the immediately preceding three financial years on corporate social responsibility (CSR)activities. The Company has a CSR committee as per the Act. Our CSR activities are primarily aimed at serving disadvantaged, vulnerable, and marginalized stakeholders from weaker socio-economic backgrounds, in the communities where we operate. In the past year, we have focused on skill development, empowering women, promoting health and well-being, providing clean water and sanitation, and developing village infrastructure.

We align our objectives with the Sustainable Development Goals (SDGs) and believe that by empowering underprivileged communities and rural areas, we can contribute to building a more inclusive and developed nation. Total expenditure incurred on Corporate Social Responsibility (CSR) activities during the year ended March 31, 2024 is H 308.97 (March 31, 2023 is H 176.16 ). The Company will set off the excess CSR amount of H 11.68 lakhs spent during the year FY 2023-24 against CSR obligation of FY 2024-25.

The major components of income tax expense and the reconciliation of expected tax expense based on the domestic effective tax rate of the Company at 25.17% (March 31, 2023: 25.17%) and the reported tax expense in the statement of profit and loss is as follows:

31. Fair value measurements (i) Fair value hierarchy

Financial assets and financial liabilities measured at fair value in the Balance Sheet are grouped into three levels of a fair value hierarchy. The three levels are defined based on the observability of significant inputs to the measurement, as follows:

Level 1: Quoted prices (unadjusted) in active markets for financial instruments.

Level 2: The fair value of financial instruments that are not traded in an active market is determined using valuation techniques which maximise the use of observable market data either directly or indirectly.

Level 3: If one or more of the significant inputs is not based on observable market data, the instrument is included in level 3.

The Company's principal financial liabilities comprise borrowings, trade and other payables. The main purpose of these financial liabilities is to finance the Company's operations. The Company's principal financial assets comprise of loans, trade and other receivables, cash and cash equivalents and other bank balances derived directly from its operations.

(iv) The carrying amounts of trade receivables, trade payables and cash and cash equivalents are considered to be the same as their fair values, due to their short-term nature. Difference between carrying amounts and fair values of bank deposits, other financial assets, other financial liabilities and borrowings subsequently measured at amortised cost is not significant in each of the years presented. For all other amortised cost instruments, carrying value represents the best estimate of fair value.

For financial assets measured at fair values, the carrying amounts are equal to the fair values.

32. Financial instruments risk management

The Company is exposed to various financial risks arising from its operations and the use of financial instruments. The key financial risks include market risk, credit risk and liquidity risk. The Company's risk management policies are established to identify and analyse the risks faced by the Company and seek to, where appropriate, minimize potential impact of the risk and to control and monitor such risks. The Company's risk management is coordinated by the Board of Directors and focuses on securing long term and short term cash flows. The Company does not engage in trading of financial assets for speculative purposes.

The following sections provide details regarding the Company's exposure to the financial risks associated with financial instruments held in the ordinary course of business and the objectives, policies and processes for management of these risks.

A. Market risk:

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk comprises two types of risk: interest rate risk and currency risk. Financial instruments affected by market risk include borrowings, deposits, trade receivables and other financial instruments.

The sensitivity analyses in the following sections relate to the position as at March 31, 2024 and March 31, 2023. The analysis exclude the impact of movements in market variables on the carrying values of gratuity and other post retirement obligations; provisions; and non-financial assets and liabilities.

i. Interest rate risk:

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company has loan facilities on floating interest rate, which exposes the Company to risk of changes in interest rates. The management monitors the interest rate movement and manages the interest rate risk based on its policies, which include entering into interest rate swaps as considered necessary. The Company's investment in deposits with banks are for short durations and therefore do not expose the Company to significant interest rate risk. Below are the details of exposure to fixed rate and variable rate instruments:

Every 0.5% increase/decrease in the interest rate component applicable to the respective borrowings would effect the Company's net profit before tax resulting in an expense/income of H21.54 and H39.54 for the year ended March 31, 2024 and March 31, 2023 respectively.

ii. Foreign currency risk:

Foreign currency risk is the risk that the value of a financial instrument will fluctuate due to changes in foreign exchange rates. The Company's exposure to the risk of change in foreign exchange rates relates primarily to the Company's operating activities (when revenue or expense is denominated in foreign currency) and financing activities (when borrowings are denominated in foreign currency), The foreign currencies in which these transactions are denominated are US Dollars, Euros, Japanese Yen, Great British Pound and Swiss Franc. The Company uses foreign exchange forward contracts to hedge its exposure in foreign currency risk.

iii. Equity price risk:

The Company's exposure to equity securities price risk arises from investments held by the Company and classified in the balance sheet as FVTOCI/FVTPL. An increase/(decrease) in fair value of investments by 10% shall impact the Company's equity and total comprehensive income by H12.79 (March 31, 2023: H5.25).

B. Credit risk

Credit risk is the risk that a counterparty fails to discharge an obligation to the Company, leading to a financial loss. The Company is mainly exposed to the risk of its balances with the bankers and trade and other receivables. None of the Company's cash equivalents, other bank balances, loans and security deposits were past due or impaired as at March 31, 2024 and March 31, 2023.

C. Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due. The Company manages its liquidity risk by ensuring, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risk to the Company's reputation.

Management monitors rolling forecasts of the Company's liquidity position (comprising the undrawn borrowing facilities) and cash and cash equivalents on the basis of expected cash flows.

33. Capital risk management

The Company's objective when managing capital is to safeguard the Company's ability to continue as a going concern in order to provide returns for shareholders and benefits for stakeholders and to maintain an optimal capital structure to reduce the cost of capital. Hence, the Company may adjust any dividend payments, return capital to shareholders or issue new shares or sell assets to reduce debt. Total capital is the equity as shown in the statement of financial position. Currently, the Company primarily monitors its capital structure on the basis of the following gearing ratio. Management is continuously evolving strategies to optimize the returns and reduce the risks. It includes plans to optimize the financial leverage of the Company.

During the previous year, the Board of Directors of the Company approved transfer of Company's property by way of perpetual lease to various parties, subject to receipt of requisite approvals. The transaction is yet to receive approval of regulatory authorities.

37. Goodwill

Pursuant to the Scheme of Amalgamation and Arrangement ("the Scheme") duly approved by the National Company Law Tribunal, Hyderabad Bench vide their order dated March 21, 2018, Neuland Health Sciences Private Limited ("NHSPL") and Neuland Pharma Research Private Limited ("NPRPL") (together referred to as "Transferor Companies"), were merged with the Company with appointed date of April 01, 2016. NHSPL is engaged in the business of conducting research and development of Peptides and NPRPL is in the business of contract research services.

The purchase consideration of H31,084.99 paid by way of issue of 22,70,635 equity shares of H10 each [in accordance with the Scheme, 45,90,608 equity shares of H10 each held by NHSPL in the Company stands cancelled and the Company shall issue 68,61,095 and 148 fully paid-up equity shares of H10 each to the shareholders of NHSPL and NPRPL respectively] at a premium of H1,359 per equity share.

Excess of consideration paid over net assets taken over aggregating to H27,946.10 is recognized as Goodwill.

The recoverable amount of the above cash generating unit ("CGU") has been assessed using a value-in-use model. The recoverable value is computed based on the net present value of the projected post-tax cash flows plus a terminal value of the cash generating unit to which the goodwill is allocated. Initially a post-tax discount rate is applied to calculate the net present value of the post-tax cash flows. The cash flow projections include specific estimates for five years developed using internal forecasts and a terminal growth rate thereafter of 5%. The planning horizon reflects the assumptions for short-to-mid term market developments which are based on key assumptions such as margins, expected growth rates based on past experience, new product launches and management's expectations / extrapolation of normal increase / steady terminal growth rate. Discount rate reflects the current market assessment of the risks. The discount rate is estimated based on the weighted average cost of capital for the Company. Post-tax discount rates used were 14.35% for the year ended March 31, 2024. The management believes that any reasonable possible change in the key assumptions would not cause the aggregate carrying amount to exceed the aggregate recoverable amount of the cash- generating unit.

Dr. D. R. Rao and D. Sucheth Rao have extended personal guarantees in connection with the working capital limits availed by the Company which was released w.e.f October 10, 2023. (Refer Note 14)

(d) Transaction with related parties

In accordance with the applicable provisions of the Income Tax Act, 1961, the Company is required to use certain specified methods in assessing that the transactions with the subsidiaries, are carried at an arm's length price and is also required to maintain prescribed information and documents to support such assessment. The appropriate method to be adopted will depend on the nature of transactions / class of transactions, class of associated persons, functions performed and other factors as prescribed. Based on certain internal analysis carried out, management believes that transactions entered into with the related parties were carried out at arms length prices. The Company is in the process of updating the transfer pricing documentation for the financial year ended March 31, 2024. In opinion of the management, the same would not have an impact on these financial statements. Accordingly, these financial statements do not include the effect of the transfer pricing implications, if any.

39. Commitments

Estimated amount of contracts remaining to be executed on capital account and not provided for (net of advances) amounts to H5,791.13 (March 31, 2023: H950.85).

40. Contingent liabilities and pending litigations

As at

March 31, 2024

As at March 31, 2023

Disputed income tax liabilities

Assessment year 2004-05 - refer note (a) below

693.33

693.33

Other income tax matters

54.87

54.87

GST/Customs

Assessment year 2017-18 towards availment of transitional input tax credit (GST)

47.95

47.95

Assessment year 2017-18 towards Refund of un-utilised Education & Secondary Higher Education Cess & Krishi Kalyan Cess not transferred in Tran_1

64.38

64.38

ITC availed on Cancelled Dealers

5.30

-

Non- fulfilment of export obligation (customs)

-

46.25

Other Disputes/Matters

Public litigation against land parcel allotment by APIICL- refer note (b) below

1,902.76

1,934.30

CIGSR Order for land parcel at Bonthapally in survey no 490/2- refer note (c) below

0.64

0.64

CIGSR Order for land parcel at Bonthapally in survey no 490/1- refer note (d) below

3.30

3.30

Certain disputes, for unascertained amounts are pending in the Labour Courts, Telangana Since, the chance of appellants succeeding in their claims is less than probable, the Company does not expects any liability in this respect.

" Not

ascertainable "

" Not

ascertainable "

Other Claims and Guarantees

Letter of Credits, Bank Guarantees including performance bank guarantees issued by the banks on behalf of the Company

5,483.83

6,276.13

Notes:

(a) The Income tax authorities had re-opened the income tax assessment of the Company for the assessment year 200405 later than the periods permitted by the provisions of the Income Tax Act, 1961 and thereby demanded an additional tax amount of H693.33 on account of disallowance of certain prior period expenditure recognized by the Company in the computation of gross total income for the assessment year then ended. Aggrieved by the order of the Income Tax department, the management had filed an appeal with the higher authorities which had been successfully decided in favour of the Company. The Income Tax department has however filed an appeal with the Hon'ble High Court of Telangana in this regard, which is pending final outcome. However, on the basis of its internal assessment and considering the order of the first level appellate authority, the Company is confident of securing an favourable order from the High Court and accordingly, no adjustments have been made to the standalone financial statements in this regard.

Other pending litigations / contingent liabilities:

(b) During 2004, the Company was allotted land parcel by the then Andhra Pradesh Industrial Infrastructure Corporation Limited ("APIIC") for setting up a basic research and development center. Subsequently public interest litigation was filed challenging allotments made by APIIC as unconstitutional and to cancel the allotments and resume the lands in all cases where the development has not commenced or the substantial progress has not been made as per the terms of allotments and regulations. The Company has been named as one of the parties to the said public interest litigation and the case is currently pending for hearing at Hon'ble High Court of Telangana. If there is an adverse ruling against the Company, the estimated financial impact on the Company could be H1,902.76.

(c) Our Company purchased land in Survey No. 490/2 situated at Bonthapally Village, Jinnaram Mandal, Medak District. The Revenue department issued notices to our Company for resumption of the said land on the ground that the same was "assigned land" Our Company has filed an application before the Collector, Medak District for regularization of the said land as per the applicable laws. Our Company also filed a writ petition before the High Court praying for an order not to take any coercive steps. The High Court vide its order dated March 18, 2011 directed the revenue department to not take any coercive steps till the disposal of the representation filed by our Company.

The matter is pending before the Collector, Medak District. The management believes that the outcome will be in favour of the Company and hence no adjustment is made in the financial statements.

(d) During the financial year ended March 31, 2008, the Commissioner and Inspector General of Stamps and Registration (CIGSR), Andhra Pradesh has vide it's order dated February 22, 2008 has cancelled the registration of the land parcel owned by the company situated at Bonthapally pursuant to complaint made by one of the seller. Aggrieved by the aforesaid order the Company has filed a writ petition challenging order of CIGSR with Hon'ble High Court of Telangana (the 'Court') as the Company was not involved during the proceedings. The Court has vide its order dated December 31, 2010 has directed to maintain the status quo with regards to the possession of the property till further orders passed. Proceedings of the case are still pending with the court. The management is confident that orders will be in the favour of the Company, hence no adjustment is deemed necessary to these standalone financial statements.

41. Leases

The Company has entered into operating leases of office premises and residential bungalow, with no restrictions and are renewable at the option of either of the parties, for a period of 3 years to 5 years. The escalation rates is 5% per annum as per the terms of the lease agreement. There are no sub leases. The Company applies the short term lease and lease of low value assets recognition exemption for few leases.

1. The aggregate depreciation expense on right-of-use assets of H 321.35 is included under depreciation and amortization expense in the Statement of Profit and Loss.

2. Rental expense recorded for short-term and low value leases was H 33.44 for the year ended March 31, 2024.

3. The Company does not face a significant liquidity risk with regard to its lease liabilities as the current assets are sufficient to meet the obligations related to lease liabilities as and when they fall due.

43. Segment reporting

In accordance with Ind AS 108 - 'Operating segments' segment information has been given in the consolidated financial statements of the Company and therefore no separate disclosure on segment information is given in these standalone financial statements.

44. The Code on Social Security 2020 ('the Code') relating to employee benefits, during the employment and post-employment, has received Presidential assent on September 28, 2020. The Code has been published in the Gazette of India. Further, the Ministry of Labour and Employment has released draft rules for the Code on November 13, 2020. However, the effective date from which the changes are applicable is yet to be notified and rules for quantifying the financial impact are also not yet issued. The Company will assess the impact of the Code and will give appropriate impact in the financial statements in the period in which, the Code becomes effective and the related rules to determine the financial impact are published.

45. The Company has a process whereby periodically all long term contracts (including derivative contracts) are assessed for material foreseeable losses. At the year end, the Company did not have any long-term contracts (including derivative contracts) for which there were any material foreseeable losses.

46. Other Statutory Information:

i The Company does not have any Benami property, where any proceeding has been initiated or pending against the company for holding any Benami property.

ii The Company has not been declared willful defaulter by any bank or financial institution or government or any government authority.

iii The Company does not have any transactions with companies struck off under section 248 of the Companies Act, 2013 or section 560 of Companies Act, 1956.

iv The Company does not have any charges or satisfaction which is yet to be registered with ROC beyond the statutory period.

v The company has complied with the number of layers prescribed under clause (87) of section 2 of the Act read with the Companies (Restriction on number of Layers) Rules, 2017.

vi The company has not entered into any scheme of arrangement which has an accounting impact on current or previous financial year.

vii No funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries") with the understanding, whether recorded in writing or otherwise, that the Intermediary shall lend or invest in party identified by or on behalf of the Company (Ultimate Beneficiaries).

The Company has not received any fund from any party(s) (Funding Party) with the understanding that the Company shall whether, directly or indirectly lend or invest in other persons or entities identified by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

viii The Company does not have any undisclosed income which is not recorded in the books of account that has been surrendered or disclosed as income during the year (and previous year) in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961.

47. The standalone financial statements are approved for issue by the Company's Board of Directors on May 10, 2024.